NV-CoV-2

N/A

Report date: 2024/06/20 17:08:12
NMEFirst In Class

Base Information

Drug NameNV-CoV-2
Drug Alias NameNVCoV2NVCoV-2NV-387
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionVirus internalization inhibitorsSARS-CoV-2 Spike glycoprotein receptor binding domain antagonists
TargetsSARS-CoV-2 Spike glycoprotein receptor binding domain
Therapy Area/IndicationsCoronavirus Disease 2019 (COVID-19)SmallpoxMonkeypox
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesIndia
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaN/A
Originator CompaniesTheraCour Pharma Inc
China Registration ClassN/A

Develop Information

Active CompaniesKarveer Meditech Pvt LtdNanoViricides IncNanoviricides +[4] 
Inactive CompaniesN/A
Active IndicationsCoronavirus Disease 2019 (COVID-19)SmallpoxMonkeypox
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A